Licensees

Agendia™ B.V. (The Netherlands) - AviaraDx licensed the Molecular Cancer Identification technology to Agendia in 2004 for development of a molecular test to identify the origin of metastatic cancer from patients with carcinoma of unknown primary (CUP). Agendia launched its CupPrint™ test for the European market in May 2005. (Press Release) The CupPrint™ test is a microarray-based platform consisting of the simultaneous measurement of 1,500 genes contained on a proprietary microarray manufactured by Agilent Technologies for authorized licensees.

Laboratory Corporation of America® Holdings - AviaraDx licensed the Molecular Cancer Identification RT-PCR technology to LabCorp in 2005 for development of a molecular test to identify the origin of metastatic cancer from patients with carcinoma of unknown primary (CUP). (Press Release) The LabCorp CUP test* is now available through LabCorp and its US LABS division.

*The performance characteristics of this test have been determined by LabCorp. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). LabCorp is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and is certified as qualified to perform high complexity testing. The result should not be used as a diagnostic procedure without confirmation of the diagnosis by a diagnostic product or procedure.

Quest Diagnostics® - AviaraDx licensed the Molecular Cancer Identification technology to Quest Diagnostics in 2005 for development of a molecular test to identify the origin of a metastatic cancer from patients with carcinoma of unknown primary (CUP). Quest began marketing its CUP test** in April 2006, concurrent with a peer reviewed publication of the MCID technology and the receipt of New York state approval. (Press Release) In addition, AviaraDx licensed its Breast Cancer Profiling technology to Quest Diagnostics in 2005 for development of a molecular test for risk of recurrence. Quest began marketing its H/I Breast Cancer Recurrence Assay *** in December 2006. (Press Release)

**This test was developed based upon AviaraDx, Inc. Molecular Cancer Identification technology and its performance characteristics determined by Quest Diagnostics Nichols Institute. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. These results are adjunctive to the ordering physician's work-up.

***This test was developed based upon AviaraDx, Inc. Breast Cancer Profiling technology and its performance characteristics determined by Quest Diagnostics Nichols Institute.  It has not been cleared or approved by the U.S. Food and Drug Administration.  The FDA has determined that such clearance is not necessary.  This test is used for clinical purposes.  It should not be regarded as investigational or for research. These results are adjunctive to the ordering physician's work-up.

| TOP |